|
Tetrathiomolybdate Clinical Trials
1 actively recruiting trial across 1 location
No change since May 2026
Also known as: TM
Pipeline
Phase 1/2: 1
Top Sponsors
- Dartmouth-Hitchcock Medical Center1
Indications
- Residual Disease1
- Triple Negative Breast Cancer1
- Breast Cancer1
- Cancer1
Indianapolis, Indiana1 trial
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Indiana University Simon Cancer Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.